Action News Jax
by Lorena Inclan
Dr. Nilufer Ertekin-Taner a Professor of Neurology at Mayo Clinic, said FTD impacts tens of thousands of people in the U.S. alone. Right now, Mayo Clinic is working on trying to find a cause. “Unfortunately, right now we do not have therapies that can stop this disease, that can turn back the clock,” said Ertekin-Taner. According to Ertekin-Taner, the fact that FTD impacts younger people could delay a proper diagnosis. “It is a very big concern because of the very young age of onset. One might not even think that that patient might have a form of dementia,” she said.
Context: Nilufer Taner, M.D., Ph.D. is a Mayo Clinic neurologist. Dr. Ertekin-Taner's laboratory aims to discover and characterize the genetic factors that influence the risk of AD and other neurodegenerative diseases, such as progressive supranuclear palsy (PSP), through the use of combined genomic, transcriptomic and epigenetic approaches. You can read more about her research here.
Contact: Kevin Punsky